Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Legend Biotech Corp.

http://www.legendbiotech.com

Latest From Legend Biotech Corp.

IPO Update: 58 Drug Developers Raised $12.5bn Through Q3

The average return for companies that went public in the US through the end of September was 49.4% as of 5 October. The fourth quarter started with four additional initial public offerings on 1 October.

Financing Growth

China Detains Legend Biotech CEO, Exposes Genetic Material Minefield

Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.

Research & Development Clinical Trials

Approval Of BMS/Bluebird’s Ide-Cel May Come Just In Time

In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.

Drug Review ImmunoOncology

Poseida Sinks On Prostate Cancer CAR-T Clinical Hold

Poseida’s technologies are designed to deliver safer, more effective cell and gene therapies, but the first trial for its autologous PSMA-targeting CAR-T therapy was put on a clinical hold after a patient died.

Clinical Trials Drug Safety
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
UsernamePublicRestriction

Register